

A white paper on **Fatty Liver Disease: A Present and Growing Threat**

(This White Paper on Fatty Liver Disease was prepared for the KCF-GKF session on September 26th, 2026, using publicly available information)

1. Introduction

Fatty liver disease is the excess accumulation of fat in liver cells. It has quietly become the most common chronic liver condition in the world. It was long known as non-alcoholic fatty liver disease (NAFLD); in 2023, an international consensus renamed it metabolic dysfunction-associated steatotic liver disease (MASLD) to better reflect its roots in obesity, insulin resistance, and metabolic syndrome.

The disease begins as simple fat deposition (steatosis), which in a subset of people progresses to inflammation and liver-cell injury (steatohepatitis, NASH/MASH), then to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma.

What makes this a public-health emergency rather than a niche medical concern is its scale and silent progression: most affected people have no symptoms until the disease is advanced. Its rise tracks closely with rising obesity, type 2 diabetes, and sedentary urban living trends that are especially pronounced across South Asia, including Jammu & Kashmir and the rest of India.

This document reviews incidence and trend data across India, including J&K, and South Asia over recent decades; the causes and risk factors; the chronic diseases that follow when it goes uncontrolled; and the lifestyle changes proven to prevent, halt, or reverse it.

2. Has Fatty Liver Disease Increased Over Recent Decades?

Population-representative data on fatty liver disease only became available from the 1990s onward, once liver ultrasound and blood-based screening became widespread, so a true 50-year trend line does not exist. However, every large trend analysis that does exist, spanning roughly three decades, shows a steep and consistent rise, and clinicians report that the disease has moved from an uncommon incidental finding to an everyday diagnosis.

A widely cited meta-analysis of global data found that pooled NAFLD prevalence rose by roughly half in one generation; from about 25.3% in 1990–2006 to 38.0% in 2016–2019. Using the Global Burden of Disease (GBD) framework, another analysis estimated that between 1990 and 2021 the number of people living with fatty liver disease worldwide grew from about 561 million to 1.27 billion, a rise of roughly 125%, while new cases diagnosed each year rose by about 95%. This corresponds to an all-age prevalence rise from roughly 10.6% to 16.1% of the global population, which is a different, broader denominator than the *adult-only* pooled estimates of 25.3%–38.0% cited above, so the two figures are not directly comparable, though both point the same direction.

South Asia (India, Pakistan, Bangladesh, Nepal, Sri Lanka) is among the most heavily affected regions, with pooled adult prevalence estimated at roughly 34% — comparable to, or higher than, many high-

income countries, despite lower average body-mass index. A 2023 meta-analysis covering studies from 2004–2021 found South Asian NAFLD prevalence to be high across both rural (~23%) and urban (~33%) communities, climbing to over 54% among people who already have components of metabolic syndrome. Within India specifically, a systematic review and meta-analysis pooling 23,581 participants across single- and multi-centre studies estimated overall adult NAFLD prevalence at 38.6%, with the disease detected in essentially every Indian state studied.

A rigorously designed community-based study comparing urban Delhi and rural Ballabgarh (Haryana) found even higher, age- and sex-standardised figures — 65.7% in urban and 61.1% in rural adults — well above the 19–32% reported by earlier Indian community surveys conducted a decade or more before. This gap shows a steep within-country rise, though it also partly reflects differences in study population, diagnostic method, and time period, so compare the figures with caution.

Region-specific data for J&K are more limited than for larger Indian states, but the available clinical and hospital-based evidence points in the same direction. Gastroenterologists in Srinagar report that fatty liver now affects an estimated 23–30% of the Kashmir Valley's population, with some physicians warning that close to one-third of residents may be affected when alcoholic and metabolic fatty liver disease are combined.

Taken together, this evidence, global GBD modelling, national Indian meta-analyses, South Asian pooled data, and Kashmir-specific clinical reports support a clear conclusion: fatty liver disease has increased substantially in prevalence over the period for which data exist (roughly the last three to four decades), and clinicians in J&K describe an accelerating rise within just the last five to ten years.

2.1 Summary of reported prevalence

No	Population/Study	Period	Reported Prevalence
1	Global (pooled adult estimates)	1990 - 2006	~ 25.3%
2	Global (pooled adult estimates)	2016 - 2019	~ 38.0%
3	Global (GBD 2021 modelling, all ages)	1990 → 2021	10.6% → 16.1%
4	South Asia (pooled meta-analysis)	2004 - 2021	~ 33.8% (Range 22.9–46.8%)
5	India (national meta-analysis, adults)	up to 2021	38.6%
6	Urban Delhi / rural Ballabgarh, India	2017- 2019	65.7% urban/61.1% rural
7	Kashmir Valley (linical estimates)	2025 - 2026	~ 23 - 30% (up to ~1/3 of population)

Note: Differences between studies partly reflect diagnostic method (ultrasound vs. transient elastography vs. blood-based indices), study setting (community vs. hospital), population age range (all-age vs. adults-only), and the specific population sampled. Figures are therefore not perfectly comparable across rows, but the directional trend — a substantial rise over time — is consistent.

3. Causes and Risk Factors

Fatty liver disease is best understood as the hepatic (liver) manifestation of metabolic syndrome. It arises when the liver's capacity to process and export fat is overwhelmed, usually driven by insulin resistance. Key drivers include:

1. **Obesity and central (abdominal) adiposity** — the strongest single risk factor globally, though South Asians frequently develop fatty liver at a lower body-mass index than Western populations because of a predisposition to visceral fat (the "lean NAFLD" or "metabolically obese, normal weight" phenotype).
2. **Type 2 diabetes and insulin resistance** — an estimated 55–59% of people with type 2 diabetes have coexisting fatty liver, and the two conditions drive each other in a bidirectional relationship.
3. **Dyslipidaemia** — high triglycerides and low HDL cholesterol.
4. **Hypertension**, as part of the broader metabolic syndrome cluster.
5. **Dietary patterns** — diets high in refined carbohydrates, added sugar, and fructose (especially sugar-sweetened beverages), and high in fried or processed foods, but low in fibre, protein, fruit, and vegetables.
6. **Sedentary lifestyle and low physical activity**, increasingly common with urbanisation and desk-based work.
7. **Genetic predisposition** — variants such as *PNPLA3* are more common in South Asian and other Asian populations and independently raise risk even at normal weight.
8. **Regional/environmental factors specific to J&K** — long winters that reduce outdoor physical activity, traditional calorie-dense winter diets rich in fats and carbohydrates, and increasingly sedentary habits, layered onto genetic susceptibility.
9. **Alcohol use** — a separate but overlapping contributor; regional reports note rising alcohol-associated liver disease alongside metabolic fatty liver in Kashmir.
10. **Other, less common causes** — certain medications (e.g., corticosteroids, tamoxifen, amiodarone, methotrexate), rapid weight loss, and rare metabolic or genetic disorders.

4. Consequences If Left Uncontrolled: Progression to Other Chronic Diseases

Fatty liver disease rarely exists in isolation — it is now understood as a systemic metabolic disorder that both results from, and drives, other chronic diseases. If unaddressed, it can progress along two parallel tracks: liver-specific disease and extrahepatic (whole-body) disease.

4.1 Liver - specific progression. Simple steatosis can progress to steatohepatitis (inflammation and cell injury), then to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer). In parts of North India, including J&K, rising fatty liver disease is now cited as a growing cause of hepatocellular carcinoma, even as viral hepatitis declines as the dominant cause.

4.2 Type - 2 diabetes mellitus. The relationship between fatty liver and diabetes is bidirectional: fatty liver increases the risk of developing type 2 diabetes by worsening insulin resistance, while diabetes accelerates the progression of fatty liver to steatohepatitis, fibrosis, and cirrhosis. People with both conditions face substantially higher risk of liver-related and overall complications than those with either condition alone.

4.3 Cardiovascular disease. Cardiovascular disease, not liver failure, is the leading cause of death in people with fatty liver disease. The condition is independently linked to atherosclerosis and endothelial dysfunction through shared mechanisms of insulin resistance, chronic low-grade inflammation, and abnormal lipid handling, elevating the risk of heart attack and stroke even after accounting for traditional cardiovascular risk factors.

4.4 Chronic Kidney disease. Fatty liver disease is independently associated with an increased incidence of chronic kidney disease, with risk rising further in the presence of steatohepatitis or liver fibrosis. In people with type 2 diabetes, the combination of fatty liver and chronic kidney disease carries a markedly higher risk of heart attack, stroke, and death than either condition alone; in one large Korean cohort of over 1.6 million people with diabetes, those with both conditions had roughly double the mortality risk of those with neither.

4.5 Other associations. Emerging evidence also links fatty liver disease to sarcopenia (muscle loss), cognitive decline, polycystic ovary syndrome, obstructive sleep apnoea, and increased susceptibility to certain infections — underscoring its role as a systemic, not purely hepatic, disease.

5. Prevention and Control: Corrective Steps and Lifestyle Changes

There is currently no universally approved medication that cures fatty liver disease on its own, though some diabetes and weight-loss drugs show benefit. Lifestyle change remains the cornerstone of prevention, treatment, and reversal at every stage short of advanced cirrhosis, and clinical research shows that even modest, sustained change produces measurable improvement.

5.1 Weight management

- a) Losing 5% of body weight can reduce liver fat (steatosis).
- b) Losing 7% or more can resolve steatohepatitis (active liver inflammation) in many patients.
- c) Losing 10% or more can lead to regression or stabilisation of liver fibrosis (scarring).
- d) For people who are not overweight by standard cutoffs but have a South Asian ("lean NAFLD") phenotype, guidelines recommend a lower BMI threshold for concern (about 23 kg/m² for Asian populations) and a more modest but still meaningful weight-loss target of 3–5%.

5.2 Dietary changes

- a) Adopt a Mediterranean-style or similarly balanced dietary pattern — rich in vegetables, fruit, whole grains, legumes, nuts, and unsaturated fats such as olive oil, with limited red and processed meat.
- b) Sharply reduce added sugar and fructose, especially sugar-sweetened beverages, which are strongly linked to fatty liver even in lean individuals.
- c) Reduce refined carbohydrates (white rice, refined flour) in favour of fibre-rich whole grains — particularly relevant given traditional carbohydrate-heavy diets in parts of South Asia.
- d) Limit fried and highly processed foods, and reduce saturated- and trans-fat intake.
- e) When weight loss is the goal, aim for a modest, sustained calorie deficit (roughly 500–1,000 kcal/day below maintenance, or a target of about 1,200–1,500 kcal/day), ideally under medical or dietetic guidance.

5.3 Physical activity

- a) Aim for at least 150 minutes per week of moderate-intensity aerobic activity (brisk walking, cycling, swimming), which reduces liver fat even without significant weight loss.
- b) Add resistance/strength training, which is particularly beneficial in lean and non-obese fatty liver phenotypes.

- c) Reduce total sedentary time (prolonged sitting), which is associated with higher risk independent of exercise.

5.4 Other modifiable factors

- a) Limit or avoid alcohol, which compounds liver injury even in metabolic (non-alcoholic) fatty liver disease.
- b) Prioritise adequate, regular sleep — short or poor-quality sleep is independently associated with fatty liver risk.
- c) Stop smoking, which worsens metabolic and cardiovascular risk alongside liver disease.
- d) Actively manage coexisting conditions — blood sugar (diabetes), blood pressure (hypertension), and cholesterol/triglycerides (dyslipidaemia) — through both lifestyles change and, where needed, medication under medical supervision.
- e) Undergo periodic health screening (liver-function blood tests, abdominal ultrasound, and, where available, FibroScan/transient elastography), particularly for people with obesity, diabetes, or a family history, since the disease is usually silent until advanced.

5.5 Public-health measures

Given the regional pattern of low winter physical activity and calorie-dense traditional diets in J&K, region-specific public-health measures are needed alongside individual lifestyle change: community awareness campaigns on fatty liver as a silent disease; encouragement of indoor physical activity options during long winters; school and workplace health-screening programmes; incorporation of NAFLD/MASLD screening into routine diabetes and hypertension check-ups, given the strong overlap; and expansion of low-cost ultrasound-based screening access outside major tertiary centres such as Srinagar.

6. Conclusion

Fatty liver disease has risen sharply over the last three to four decades — the period for which reliable data exist — both globally and, markedly, across South Asia, India, and the Kashmir Valley, tracking the parallel rise in obesity, type 2 diabetes, and sedentary urban living. Left unaddressed, it does not remain confined to the liver: it substantially raises the risk of type 2 diabetes, cardiovascular disease, chronic kidney disease, and ultimately cirrhosis and liver cancer.

The reassuring counterpoint is that fatty liver disease is, at most stages, preventable and reversible through sustained lifestyle change — modest weight loss, a balanced low-sugar diet, regular physical activity, limited alcohol, adequate sleep, and control of associated conditions like diabetes and hypertension.

For a region like J&K, where clinical reports suggest a fast-rising and still under-screened burden, early population-level awareness and screening, paired with individual lifestyle change, represent the most effective available strategy to prevent this silent disease from becoming a much larger driver of chronic illness in the coming decades

Disclaimer: This White Paper on Fatty Liver Disease was prepared for the KCF-GKF session on September 26, 2026, using publicly available information. Please consult with your primary care physician and hepatologist for your healthcare needs.

References for Further Reading

1. Duseja A, et al. *Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis*. Journal of Clinical and Experimental Hepatology / PMC9168741. Indian National Association for Study of the Liver, 2022.
2. *Incidence of Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) in the Female Population of North Karnataka: A Cross-Sectional Study*. PMC11375481.
3. *Rural-Urban Differentials in Prevalence, Spectrum and Determinants of Non-alcoholic Fatty Liver Disease in North Indian Population*. PMC8830644.
4. *Non-alcoholic Fatty Liver Disease in Northeast India: A Narrative Review of Rising Metabolic Syndrome*. Egyptian Liver Journal, Springer Nature, 2026.
5. *Prevalence and Associated Factors for Non-alcoholic Fatty Liver Disease Among Adults in the South Asian Region: A Meta-analysis*. The Lancet Regional Health – Southeast Asia; PMC10442973, 2023.
6. *Fatty Liver Affects 23–30% of Kashmir's Population: Dr Wahid Akbar*. Kashmir News Observer / Kashmir Thunder, April 2026.
7. *Fatty Liver Emerging as Major Health Concern in Kashmir, Doctors Warn*. The Kashmir Images, April 2026.
8. *Unveiling a Hidden Burden: The Alarming Prevalence of Metabolic Fatty Liver Disease in Pregnant Women of Kashmir*. International Journal of Medical and Pharmaceutical Research (IJMPR), 2025.
9. *Etiology, Clinical Profile, and Treatment Pattern of Hepatocellular Carcinoma at a Tertiary Care Center in North India*. Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar; Cancer Research, Statistics, and Treatment, 2023.
10. *J&K: Fatty Liver Cases Rising as Lifestyle Diseases Surge*. Morning Kashmir, July 2026.
11. Younossi ZM, et al. *The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH): A Systematic Review*. Hepatology, 2023;77:1335–47.
12. *2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis*. Clinical Gastroenterology and Hepatology, 2021.
13. *The Prevalence and Incidence of NAFLD Worldwide: A Systematic Review and Meta-analysis (using GBD 2021 data)*, 2022.
14. *Changing Epidemiology, Global Trends and Implications for Outcomes of NAFLD*. Journal of Hepatology (ScienceDirect), 2023.
15. *The Burden of Nonalcoholic Fatty Liver Disease (NAFLD) Is Rapidly Growing in Every Region of the World from 1990 to 2019*. PMC10545420.
16. *Global, Regional, and National Burden of NAFLD in Youths and Young Adults Aged 15–39 Years, 1990–2021, and Projections to 2035: Global Burden of Disease Study 2021*. Frontiers in Nutrition, PMC11810722, 2025.
17. *Combined Effects of Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease on the Risk of Cardiovascular Disease in Patients with Diabetes*. PMC9219946.
18. *Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review*. PMC12467166.
19. *The Transition from NAFLD to MASLD: Implications for Diagnosis, Prognosis, and Clinical Management*. Exploration Publishing, 2025.
20. *The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment*. Journal of Clinical Medicine, 2025;14:428. PMC11765821.
21. *The Emerging Phenotype of Nonalcoholic Fatty Liver Disease in Lean Individuals: What's Different?* Frontiers in Endocrinology, 2025.
22. American Gastroenterological Association. *Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease (NAFLD): Clinical Practice Update*.
23. American Gastroenterological Association. *Diagnosis and Management of Nonalcoholic Fatty Liver Disease (NAFLD) in Lean Individuals: Clinical Practice Update and Expert Review*. PMC9398982.
24. *Lifestyle Intervention for Metabolic Dysfunction-Associated Fatty Liver Disease: A 24-h Integrated Behavior Perspective*. PMC11450077.
25. *Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?* PMC6950597.

26. *Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment.* PMC9817050.
27. Malik AL, Yousuf NM, Ahad WA, Maqsood D, Usaid S, Tahir K, Islam J, Ayoob W, Andrabi K, Ahmad A, Shafi A. *Management of Non-alcoholic Fatty Liver Disease in Adults: An Update.* Department of General Medicine, SKIMS Medical College Hospital, Bemina, Srinagar. *Journal of Gastroenterology and Hepatology (JJGH)*, 2022.
28. Nissar UI Ashraf. *Crosstalk Between Epigenetics and Autophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease.* Department of Biochemistry, Government College for Women, Nawakadal, Srinagar. PMC, 2025.
29. Zargar AH, Bhansali A, Majumdar A, et al. *Management of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) — An Expert Consensus Statement from Indian Diabetologists' Perspective.* SKIMS, Srinagar (Endocrinology). *Diabetes, Obesity and Metabolism*, 2025 (Suppl. 4): 3–20. DOI: 10.1111/dom.16496.
30. *Ultrasound-Based Study on Anthropometric and Biochemical Correlates of NAFLD.* Department of Radiodiagnosis and Imaging, SKIMS Medical College, Bemina, Srinagar. 182 subjects (91 NAFLD cases, 91 matched controls) assessed via standardised ultrasound grading. Published via OALib/institutional repository.
31. *Metabolic Syndrome in Adults with Nonalcoholic Fatty Liver Disease.* Authors from Endocrinology (GMC Baramulla), Nephrology (GMC Srinagar), and Pathology (GMC Srinagar), with SKIMS collaboration. *Journal of Renal and Hepatic Disorders*.
32. Kapoor A, Chowdary S, Dewan D, Dev G, Kumari R, Kumar D. *Prevalence of NAFLD Among Adults Aged 30+ in a Rural Population of Jammu — An Observational Study.* Community-based study (n=322) in Block RS Pura, Jammu, under the HDSS. *National Journal of Community Medicine*, Nov 2018.

